Comparison of intermediate and high dose valaciclovir for the prophylaxis of CMV viraemia in allogeneic stem cell transplant recipients
ISRCTN | ISRCTN78766104 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN78766104 |
Secondary identifying numbers | N0256114044 |
- Submission date
- 12/09/2003
- Registration date
- 12/09/2003
- Last edited
- 30/11/2015
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Michael Potter
Scientific
Scientific
Department of Haematology
The Royal Free & University Medical School
Pond Street
Hampstead
London
NW3 2QG
United Kingdom
Study information
Study design | Randomised controlled trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Hospital |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
Scientific title | Comparison of intermediate and high dose valaciclovir for the prophylaxis of CMV viraemia in allogeneic stem cell transplant recipients |
Study objectives | Does high does valaciclovir four times daily have greater efficacy in reducing CMV viraemia than valaciclovir in allogeneic stem cell recipients? |
Ethics approval(s) | Not provided at time of registration |
Health condition(s) or problem(s) studied | Infections and Infestations: Cytomegalovirus (CMV) infection |
Intervention | Randomised controlled trial. |
Intervention type | Other |
Primary outcome measure | 1. Rate of CMV viraemia 2. Time to CMV viraemia 3. Incidence of CMV disease 4. Survival |
Secondary outcome measures | Not provided at time of registration |
Overall study start date | 03/07/2002 |
Completion date | 01/07/2004 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Not Specified |
Sex | Not Specified |
Target number of participants | 110 |
Key inclusion criteria | 110 patients, 55 in each treatment arm. |
Key exclusion criteria | Does not match inclusion criteria |
Date of first enrolment | 03/07/2002 |
Date of final enrolment | 01/07/2004 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
The Royal Free & University Medical School
London
NW3 2QG
United Kingdom
NW3 2QG
United Kingdom
Sponsor information
Department of Health (UK)
Government
Government
Richmond House
79 Whitehall
London
SW1A 2NL
United Kingdom
Website | http://www.doh.gov.uk |
---|
Funders
Funder type
Hospital/treatment centre
The Royal Free Hampstead NHS Trust (UK)
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |
Editorial Notes
30/11/2015: no publications found on PubMed.